elevated lipase semaglutide Comparative safety and side effects of and tirzepatide: Implications for clinical decision-making in obesity management Mechanisms of Non-alcoholic Fatty Liver
Description
AWARD-7 enrolled adult patients with T2D (A1c, 7.5%10.5%) and CKD stages 34 who were being treated with ACEi or ARBs and found that dulaglutide (0.75 or 1.5 mg subcutaneous once weekly) achieved similar glycemic control to insulin glargine but had significantly less eGFR decline (mean 0.7 vs 3.3 mL/min/1.73 m 2 , respectively
These alterations must be clinically justified and carefully documented to remain compliant
Pabreja, K
Vomiting: 20-21%
